Nuwellis, Inc.

Good day, everyone, and welcome to Noellis' third quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. You may withdraw yourself from the queue by pressing star 2. Please note this call may be recorded. I'll be standing by if you should need any assistance. It is now my pleasure to turn the program over for forward-looking statements. Vivian Cervantes, Investor Relations.

Thank you. Good morning, everyone, and welcome to Noellis' earnings conference call for the third quarter ended September 30, 2024. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask the questions, you may press star on your touchstone pad. Thank you for joining today's conference call to discuss Noelis' corporate developments and financial results for the third quarter ended September 30, 2024. In addition to myself, with us today are Nestor Jaramillo, Noelis' president and CEO, Dr. John Jeffries, our chief medical officer, as well as Rob Scott, our CFO. At 8 a.m. Eastern time today, Noelis released financial results for the third quarter 2024. If you have not received New Orleans' earnings release, please visit the investors page on the company's website. During today's call, the company will be making forward-looking statements. All forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends, as well as our estimated results or performance, are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. Please refer to the cautionary statements and discussion of risks in the company's filings to the Securities and Exchange Commission, including the latest 10-K. With that, I now would like to turn the call over to Nestor.

Thank you, Vivian, and good morning, everyone. Welcome to New Orleans' third quarter 2024 earnings conference call. On today's call, I will provide an overview of our third quarter performance and give an update on our strategic initiatives, followed by Dr. Jeffries, our chief medical officer, who will provide a summary of the recent publication on the efficacy of NWELIS in a real-world community hospital setting. Our Chief Financial Officer, Rob Scott, will then provide detailed commentary on our financial results before opening up the call for questions, followed by my closing remarks. NWELIS generated $2.4 million in revenue for the third quarter of 2024, a 2% decrease year-over-year However, sequentially, we grew 8% over Q2. While the adult category of our business saw a lower volume of patients treated during the summer month, our pediatric customer category experienced a surge in revenue of 28% compared to the same quarter of last year. Driven by three new pediatric accounts opened this quarter, including one of the largest hospital networks in Florida. We also experienced a sequential improvement in pediatric census. In addition to the pediatric account, we also opened two additional adult accounts. We are excited to continue to drive market penetration of our differentiated Aquadex ultrafiltration therapy as we leverage our body of clinical evidence. For the reminder of our customer category, critical care and heart failure were down 25 and 36% respectively on lower consumables utilization and consult sales reflecting the generally lower volume of patients treated during the summer months. One of our key initiatives for the last three years have been to build our body of clinical evidence in order to make this therapy standard of care and get into the medical society guidelines. In support of this initiative, I would like now to turn it over to Dr. Jeffries to discuss the latest addition to our growing body of clinical evidence and the impact that this clinical information may have in broad day-to-day clinical practice. Dr. Jeffries.